HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Follow-Up Questions
¿Quién es el CEO de HUTCHMED (China) Ltd?
Dr. Weiguo Su es el Chief Executive Officer de HUTCHMED (China) Ltd, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción HCM?
El precio actual de HCM es de $17.45, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de HUTCHMED (China) Ltd?
HUTCHMED (China) Ltd pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de HUTCHMED (China) Ltd?
La capitalización bursátil actual de HUTCHMED (China) Ltd es $2.9B
¿Es HUTCHMED (China) Ltd una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 16 analistas han realizado calificaciones de análisis para HUTCHMED (China) Ltd, incluyendo 9 fuerte compra, 15 compra, 3 mantener, 0 venta, y 9 fuerte venta
